DBV Technologies (DBVT)

Currency in USD
14.700
-0.160(-1.08%)
Closed·
14.7000.000(0.00%)
·
Unusual trading volume
DBVT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
14.25015.365
52 wk Range
8.51026.185
Key Statistics
Prev. Close
14.86
Open
15.05
Day's Range
14.25-15.365
52 wk Range
8.51-26.185
Volume
566.17K
Average Volume (3m)
258.25K
1-Year Change
47%
Book Value / Share
0.54
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DBVT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
40.801
Upside
+177.56%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

DBV Technologies News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

5 Buy
0 Hold
1 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 40.801
(+177.56% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Cantor Fitzgerald
Buy48.00+226.53%48.00Maintain17/07/2026
Citizens
Buy55.00+274.15%-Maintain17/07/2026
Citizens
Buy55.00+274.15%47.00Maintain01/05/2026
Goldman Sachs
Sell5.81-60.48%7.94Maintain09/04/2026
Cantor Fitzgerald
Buy48.00+226.53%-Maintain30/03/2026

DBV Technologies SWOT Analysis


Allergy Innovation
Explore DBV Technologies' groundbreaking Viaskin Peanut patch, offering a non-invasive solution for peanut allergies in children with promising clinical results
Market Potential
Delve into the projected $2 billion annual peak sales for Viaskin Peanut, driven by strong physician intent and a growing patient base
Financial Outlook
Learn about DBV's improved financial position, with $128 million in cash and potential for $180 million more, despite current cash burn concerns
Analyst Perspectives
Discover varied analyst price targets ranging from $10 to $21, reflecting optimism about DBV's future prospects in the allergy treatment market
Read full SWOT analysis

DBV Technologies Earnings Call Summary for Q2/2026

  • DBV Technologies remains on track to file its Viaskin Peanut patch BLA with FDA in Q3 2026, requesting priority review; stock fell 5.4% despite progress.
  • Company funded through Q3 2027 but burns $151.5M annually; market cap stands at $949.6M with InvestingPro rating financial health as 'weak.'
  • FDA has not requested additional data for filing; management completing final CMC discussions and biostatistics formatting before submission.
  • Supplemental BLA for toddlers (ages 1-3) planned by end-2026; Phase II THRIVE study launched in infants (6-12 months) to expand market reach.
  • Commercial infrastructure buildout underway including market access, field force planning, and manufacturing capacity review ahead of potential 2027 launch.
Last Updated: 17/07/2026, 08:06 am
Read Full Transcript

Earnings

Latest Release
30/04/2026
EPS / Forecast
-0.11 / --
Revenue / Forecast
900K / --
EPS Revisions
Last 90 days

DBVT Income Statement

Compare DBVT to Peers and Sector

Metrics to compare
DBVT
Peers
Sector
Relationship
P/E Ratio
−5.0x4.5x−0.4x
PEG Ratio
−0.110.570.00
Price/Book
5.5x2.2x2.6x
Price / LTM Sales
174.8x4.6x3.0x
Upside (Analyst Target)
216.3%73.5%53.5%
Fair Value Upside
Unlock8.2%9.0%Unlock

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Employees
170

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
9.53M3.22%140.13M
Other Institutional Investors
358.18M96.78%5.27B
Public Companies & Retail Investors
0.000.00%0.00
Total
367.71M100.00%5.41B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Adage Capital Management, L.P.9.18%27,178,192399,519
MPM BioImpact LLC8.81%26,066,806383,182

People Also Watch

2.60
DBV
-7.13%
19.170
ERAS
+0.79%
40.74
TBBB
+1.39%
186.16
RVMD
+3.90%
118.86
MIRM
+1.28%

FAQ

What Is the DBV Technologies (DBVT) Stock Price Today?

The DBV Technologies stock price today is 14.700 USD.

What Stock Exchange Does DBV Technologies Trade On?

DBV Technologies is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for DBV Technologies?

The stock symbol for DBV Technologies is "DBVT."

What Is the DBV Technologies Market Cap?

As of today, DBV Technologies market cap is 880.090M USD.

What Is DBV Technologies's Earnings Per Share (TTM)?

The DBV Technologies EPS (TTM) is -0.601.

From a Technical Analysis Perspective, Is DBVT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has DBV Technologies Stock Split?

DBV Technologies has split 2 times.

How Many Employees Does DBV Technologies Have?

DBV Technologies has 170 employees.

What is the current trading status of DBV Technologies (DBVT)?

As of 19/07/2026, DBV Technologies (DBVT) is trading at a price of 14.700 USD, with a previous close of 14.860 USD. The stock has fluctuated within a day range of 14.250 USD to 15.365 USD, while its 52-week range spans from 8.510 USD to 26.185 USD.

What Is DBV Technologies (DBVT) Price Target According to Analysts?

The average 12-month price target for DBV Technologies is 40.801 USD, with a high estimate of 54.99428049 USD and a low estimate of 5.83390528 USD. 5 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +177.56% Upside potential.

What Is the DBVT Premarket Price?

DBVT's last pre-market stock price is 15.050 USD. The pre-market share volume is 7,350.000, and the stock has decreased by 0.190, or 1.280%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.